Synthesis of curcumin derivatives for suppression of castration-resistant prostate cancer

被引:2
|
作者
Gong, Shunze [1 ,4 ]
Yuan, Chixiang [1 ]
Hu, Hang [2 ,3 ,5 ]
Xu, Defeng [2 ,3 ,5 ]
机构
[1] Taizhou Vocat & Tech Coll, Taizhou, Peoples R China
[2] Changzhou Univ, Sch Pharm, Changzhou, Peoples R China
[3] Jiangsu Hope Pharm Co Ltd, Changzhou, Peoples R China
[4] Taizhou Vocat & Tech Coll, Taizhou 318000, Peoples R China
[5] Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China
关键词
androgen receptor; castration-resistant prostate cancer; curcumin derivatives; dimethylcurcumin; inhibitory activity; ANDROGEN DEPRIVATION THERAPY; DIMETHYLCURCUMIN; DEGRADATION;
D O I
10.1177/17475198241230042
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this work, 20 curcumin derivatives containing halogen atoms or nitrogen atoms were synthesized for suppression of castration-resistant prostate cancer. These curcumin derivatives were prepared by aldol condensation between the substituted benzaldehydes and acetylacetone or ethyl 3-acetyl-4-oxopentanoate. All synthesized compounds were characterized by 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, high resolution mass, ultraviolet-visible spectroscopy, fluorescence spectroscopy, and high-performance liquid chromatography. The in vitro cytotoxicity of the prepared compounds against 22Rv1 cells was evaluated by the standard MTT assay. The compounds with good inhibitory activity against 22Rv1 cells were further tested for androgen receptor suppression effect. The results show that all compounds were successfully prepared and the purities are all over 90%. Among all synthesized compounds, compound p and s exhibit better inhibitory activity against 22Rv1 cells as compared to dimethylcurcumin, compound q and r display similar inhibitory activity against 22Rv1 cells as compared to dimethylcurcumin. Compounds p-s also demonstrate enhanced androgen receptor suppression effect against 22Rv1 cells as compared to dimethylcurcumin. This work indicates that compounds p-s show promising inhibitory activity against castration-resistant prostate cancer cells by suppression of androgen receptor.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Cabazitaxel for castration-resistant prostate cancer Reply
    de Bono, Johann Sebastian
    Sartor, Oliver
    LANCET, 2011, 377 (9760): : 122 - 123
  • [42] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [43] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [44] Leading causes of castration-resistant prostate cancer
    Lu, Mingqian
    Lu, Hongda
    Kong, Qingzhi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 425 - 432
  • [45] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
  • [46] About sorafenib in castration-resistant prostate cancer
    Colloca, G.
    Checcaglini, F.
    Venturino, A.
    ANNALS OF ONCOLOGY, 2008, 19 (10)
  • [47] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [48] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [49] Sequencing of agents in castration-resistant prostate cancer
    Lorente, David
    Mateo, Joaquin
    Perez-Lopez, Raquel
    de Bono, Johann S.
    Attard, Gerhardt
    LANCET ONCOLOGY, 2015, 16 (06): : E279 - E292
  • [50] BRCA mutation and castration-resistant prostate cancer
    Spirina, L. V.
    ANNALS OF ONCOLOGY, 2018, 29